[{"id":"0ecbbf9c-749c-47d2-892d-9c137312458d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04862455","created_at":"2021-04-28T13:53:51.568Z","updated_at":"2024-07-02T16:35:09.668Z","phase":"Phase 2","brief_title":"NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer","source_id_and_acronym":"NCT04862455","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Hensify (crystalline hafnium oxide)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-04-15"}]